Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Galunisertib |
Synonyms | |
Therapy Description |
Galunisertib (LY2157299) is a TGFBR1 antagonist, which inhibits downstream signaling and may suppress tumor growth (PMID: 18039567, PMID: 32210440). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Galunisertib | LY2157299|LY-2157299 | TGFBR1 inhibitor 16 | Galunisertib (LY2157299) is a TGFBR1 antagonist, which inhibits downstream signaling and may suppress tumor growth (PMID: 18039567, PMID: 32210440). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02452008 | Phase II | Galunisertib Enzalutamide | Study of TGF-Beta Receptor Inhibitor LY2157299 and Enzalutamide in Metastatic Castration-resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT02304419 | Phase I | Galunisertib | A Study of Galunisertib on the Immune System in Participants With Cancer | Completed | USA | 0 |
NCT02906397 | Phase I | Galunisertib | A Phase I Study of Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Patients With Advanced Hepatocellular Carcinoma (HCC) | Completed | USA | 0 |
NCT02688712 | Phase II | Capecitabine + Galunisertib Fluorouracil + Galunisertib Galunisertib Fluorouracil Capecitabine | ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer | Active, not recruiting | USA | 0 |
NCT02423343 | Phase Ib/II | Galunisertib Nivolumab | A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma | Completed | USA | ESP | 0 |
NCT01246986 | Phase II | Galunisertib + Sorafenib Galunisertib | A Study of LY2157299 in Participants With Hepatocellular Carcinoma | Completed | USA | NZL | ITA | FRA | ESP | DEU | AUS | 0 |